Skip to main content

David Michael Ashley

Adjunct Professor in the Department of Neurosurgery
Neurosurgery
DUMC 2600, Durham, NC 27710
203 Research Dr MSRB1, Box 2600, Durham, NC 27710

Scholarly Works - Preprints


Anti-VEGF vascular remodeling drives germinal center B cell-rich tertiary lymphoid structures during antibody-toxin and anti-CD40 combination therapy in glioblastoma.

Preprint · April 17, 2026 Glioblastoma (GBM) is characterized by aberrant neovascularization and angiogenesis. Bevacizumab (Avastin), a monoclonal antibody targeting vascular endothelial growth factor (VEGF), is clinically used with chemotherapy for patients with GBM, yet its impac ... Full text Link to item Cite

A surgical window of opportunity trial evaluating the effect of the PCSK9 inhibitor evolocumab on tumoral MHC-I expression and CD8+ infiltration in glioma

Preprint · 2025 AbstractMany cancers evade immunosurveillance by downregulating surface major histocompatibility class (MHC)-I. Proprotein convertase subtilisin/kexin type 9 (PCSK9) promotes MHC-I degradation and is elevated in glioma. Evolocumab is a ... Full text Cite

Gene expression analysis suggests immunosuppressive roles of endolysosomes in glioblastoma

Preprint · 2023 Targeting endolysosomes is a strategy extensively pursued for treating cancers, including glioblastomas (GBMs), mainly on the basis that the intact function of these subcellular organelles is key to tumor cell autophagy and survival. Here, by gene expressi ... Full text Cite